Contrary to the case with bacterial infections, progress in the diagnosis and treatment of
invasive mycoses in cancer patients has been unsatisfactory. Amphotericin B deoxycholate …

Invasive fungal infections are devastating. Despite state-of-theart antifungal therapy, the
mortality rates for invasive infections with the three most common species of human fungal …

In comparison with the number of antibacterial drugs available, there are far fewer antifungal
compounds. Even so the number of antifungal drugs is increasing all the time. There are four …

We have yet to realize the clinical benefits of combination antifungal therapy, but the
literature is beginning to show the potential positive and negative aspects of this approach …

As invasive fungal infections in immunocompromised patients become increasingly
important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have …

Abstract Treatment of invasive fungal infections (IFIs) remains challenging, because of the
limitations of the current antifungal agents (ie, mode of administration, toxicity, and drug-drug …

Recent progress in the therapy of deep-seated mycosis is mostly due to the introduction of
new triazole derivatives for systemic use. However, many problems still remain. The number …

The availability of new antifungal agents with unique mechanisms of action and improved
tolerability has widened the possibilities for the use of combination antifungal therapy for …

Background: The antifungal armamentarium includes a number of drug classes and agents
within each class. Successful IFI management depends on optimal matching of drug choice …

Invasive mycoses present a global challenge with expansion into new hosts, emergence of
new pathogens, and development of multidrug resistance. In parallel, new antifungal agents …